Iambic Therapeutics filed for a Nasdaq IPO the same morning it announced an AbbVie collaboration. Public markets will still judge the company on whether its brain-penetrant HER2 inhibitor holds up against Enhertu and Tukysa.
Newsletter
Pipeline, markets, policy, and science. Once a week.
KRAS sat on the undruggable list for decades. Silexion's SIL204 is built to silence the mutation earlier in the cell, and the Phase 2/3 program is now moving into patients.
Definium's Phase 3 Panorama study met its primary endpoint in generalized anxiety disorder with a 5.1-point HAM-A gap, testing whether an active 50 µg control and zero psychotherapy can clear the FDA hurdle that broke Lykos.
The FDA has granted accelerated approval to Bayer's Hyrnuo as a frontline therapy in HER2-mutant lung cancer, matching rival zongertinib's response rates while carrying twice-daily meal requirements and steeper gastrointestinal toxicity.